<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583685</url>
  </required_header>
  <id_info>
    <org_study_id>H&amp;H_SWITCH-1</org_study_id>
    <nct_id>NCT02583685</nct_id>
  </id_info>
  <brief_title>Switching Regimen in Treating Cirrhotic HCV GT1b Subjects</brief_title>
  <acronym>SWITCH-1</acronym>
  <official_title>Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanity and Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanity and Health Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized study to evaluate the efficacy and safety of switching
      treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with
      CHC genotype 1b infection, who are interferon/ribavirin-intolerant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy</measure>
    <time_frame>Post treatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>To evaluate the proportion of patients adherent to therapy (both on-treatment adherence and treatment discontinuation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life evaluated with questionnaires</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <description>To evaluate the change in health-related quality of life during and after treatment with questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mental health evaluated with questionnaires</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <description>To evaluate the change in mental health during and after treatment with questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver disease progression</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Liver disease progression is a composite endpoint measured by laboratory parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, albumin, platelets, prothrombin time (PT) and α-fetoprotein) and observed or reported clinical signs and symptoms.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + ASV 4 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &lt;25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + SMV 4 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &lt;25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + ASV 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &lt;25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + SMV 6 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &lt;25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + ASV 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &gt; 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + SMV 8 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &gt; 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + ASV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &lt;2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR4 + LDV/SOF + SMV 12 wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA &lt;2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + ASV 4 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.</description>
    <arm_group_label>PR4 + LDV/SOF + ASV 4 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>Sunvepra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + SMV 4 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.</description>
    <arm_group_label>PR4 + LDV/SOF + SMV 4 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>OLYSIO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + ASV 6 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.</description>
    <arm_group_label>PR4 + LDV/SOF + ASV 6 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>Sunvepra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + SMV 6 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.</description>
    <arm_group_label>PR4 + LDV/SOF + SMV 6 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>OLYSIO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + ASV 8 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.</description>
    <arm_group_label>PR4 + LDV/SOF + ASV 8 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>Sunvepra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + SMV 8 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.</description>
    <arm_group_label>PR4 + LDV/SOF + SMV 8 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>OLYSIO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + ASV 12 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.</description>
    <arm_group_label>PR4 + LDV/SOF + ASV 12 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>Sunvepra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PR4 + LDV/SOF + SMV 12 wk</intervention_name>
    <description>Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (&lt; 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.</description>
    <arm_group_label>PR4 + LDV/SOF + SMV 12 wk</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>Copegus®</other_name>
    <other_name>Harvoni®</other_name>
    <other_name>OLYSIO®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with chronic HCV GT1b infection;

          -  HCV RNA ≥ 10000 IU/mL at screening;

          -  Received 4 weeks pegylated interferon plus ribavirin (PR4) therapy and are intolerant
             to PR4;

          -  Cirrhosis determination; a liver biopsy may be required;

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male;

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner;

          -  HIV or HBV co-infection;

          -  Hematologic or biochemical parameters at Screening outside the protocol- specified
             requirements;

          -  Active or recent history (≤ 1 year) of drug or alcohol abuse;

          -  History or current evidence of any condition, therapy, laboratory abnormality or other
             circumstance that might confound the results of the study, or interfere with the
             subject's participation for the full duration of the study, such that it is not in the
             best interest of the subject to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Lau</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanity and Health GI and Liver Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen WANG, MD, PhD</last_name>
    <phone>+85228613777</phone>
    <email>doc_chengwang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yudong WANG, PhD</last_name>
    <phone>+85228613777</phone>
    <email>ydwang@connect.hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofeng Chen, MD</last_name>
      <phone>(8610)66933427</phone>
      <email>guofengchen302@163.com</email>
    </contact>
    <investigator>
      <last_name>George KK Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guofeng Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanity and Health GI and Liver Centre</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <zip>00852</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George KK Lau, MD</last_name>
      <phone>(852)28613777</phone>
      <email>gkklau@netvigator.com</email>
    </contact>
    <investigator>
      <last_name>George KK Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

